Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NICOTINE vs NICORETTE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nicotine is a nicotinic acetylcholine receptor (n ACh R) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.
Nicotine acts as an agonist at nicotinic acetylcholine receptors, stimulating the release of neurotransmitters such as dopamine and norepinephrine, which reduces withdrawal symptoms and cravings associated with smoking cessation.
Tobacco dependence (smoking cessation) - FDA approved,Relief of nicotine withdrawal symptoms (OTC),Off-label: Treatment of ulcerative colitis, Tourette syndrome, Alzheimer's disease, and attention deficit hyperactivity disorder (limited evidence)
Relief of nicotine withdrawal symptoms and aid in smoking cessation
Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).
Nicotine replacement therapy. For smoking cessation, chewing gum: 2 mg or 4 mg piece chewed slowly for 30 minutes every 1-2 hours as needed, maximum 24 pieces/day. Transdermal patch: Apply one 7 mg, 14 mg, or 21 mg/24 hour patch daily. Lozenge: 2 mg or 4 mg lozenge dissolved in mouth every 1-2 hours, maximum 20 lozenges/day. Inhaler: 6-16 cartridges/day. Nasal spray: 1-2 doses/hour, maximum 40 doses/day. All routes: typical duration 8-12 weeks.
Terminal elimination half-life is approximately 2 hours (range 1-4 hours); short half-life leads to frequent dosing to maintain therapeutic effects.
The terminal elimination half-life of nicotine is approximately 2 hours. This short half-life necessitates frequent dosing or continuous delivery to maintain therapeutic levels. Cotinine, the major metabolite, has a half-life of 15-20 hours.
Primarily hepatic via CYP2A6 and CYP2B6 to cotinine, then further metabolized to trans-3'-hydroxycotinine. Also metabolized via glucuronidation (UGT1A4, UGT1A9). Renal excretion of metabolites.
Primarily hepatic metabolism via CYP2A6; also metabolized by glucuronidation. Major metabolite is cotinine.
Primarily hepatic metabolism (80-90%) to cotinine and nicotine-N-oxide; renal excretion of unchanged nicotine accounts for 5-10% in non-smokers and up to 30% in smokers with acidic urine; less than 2% excreted in feces via biliary elimination.
Nicotine is extensively metabolized in the liver, primarily to cotinine. Renal excretion accounts for 2-35% of nicotine elimination unchanged, depending on urine p H (acidic urine increases excretion). Biliary/fecal excretion is minimal (<5%). Total clearance is about 1 L/min, with renal clearance of about 100 m L/min.
Less than 5% bound to plasma proteins (mainly albumin).
Nicotine is <5% bound to plasma proteins, primarily albumin. It is a weak base with high volume of distribution, so protein binding is minimal.
Approximately 2-3 L/kg (range 1-4 L/kg), indicating extensive tissue distribution including brain, lungs, and skeletal muscle.
Nicotine has a large volume of distribution, ranging from 2.0 to 3.0 L/kg, reflecting extensive tissue uptake (including brain, lungs, and muscle). This accounts for its rapid distribution and large total body load.
Inhalation (smoking): 80-90% (rapid absorption); intranasal: 50-80%; transdermal: 100% (systemic absorption rate varies by patch); oral (gum/lozenge): 50-80% (buccal absorption avoids first-pass metabolism); oral (swallowed): <50% due to first-pass hepatic metabolism.
Transdermal patch: approximately 68-75% of the nicotine dose is absorbed systemically. Gum: about 50% due to buccal absorption and first-pass metabolism (swallowed portion is less bioavailable). Inhaler: approximately 50% of the dose is absorbed (buccal and pulmonary). Lozenge: similar to gum, about 50%.
No specific dose adjustment recommended; use with caution in severe renal impairment due to increased risk of accumulation.
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 m L/min): use with caution; nicotine elimination may be prolonged, but no specific dose adjustment guidelines are established. Monitor for adverse effects.
For Child-Pugh class A or B: no adjustment; Child-Pugh class C: use with caution due to reduced clearance.
No specific dose adjustment guidelines for Child-Pugh classes A or B. For severe hepatic impairment (Child-Pugh class C): use with caution; nicotine clearance may be reduced, and therapy should be initiated at the lowest effective dose with close monitoring.
Not recommended in patients <18 years except under specific clinical guidance; weight-based dosing not established.
Not recommended for use in patients under 18 years of age for smoking cessation due to lack of safety and efficacy data. In adolescents (12-17 years) who are highly nicotine dependent, off-label use may be considered with careful dose titration: patch 14-21 mg/24h for heavy smokers, or gum 2-4 mg every 1-2 hours as needed. Close monitoring for adverse effects required.
Start at lower end of dosing range (e.g., 7 mg/24 h transdermal); monitor for adverse effects due to reduced clearance.
No specific dose adjustment required; however, elderly patients may have comorbidities or concurrent medications that require cautious use. Start with the lowest effective dose (e.g., 7 mg patch or 2 mg gum) and titrate based on tolerance and nicotine dependence. Monitor for adverse effects such as dizziness, hypotension, and arrhythmias due to age-related changes in drug clearance.
WARNING: ADDICTION AND TOXICITY. Nicotine is a highly addictive substance. Keep out of reach of children and pets. Accidental ingestion or exposure can cause severe toxicity, including seizures, respiratory arrest, and death. Do not use in non-smokers or individuals with cardiovascular disease without medical supervision.
None
Risk of nicotine toxicity in children and pets; keep products safely stored,Caution in patients with cardiovascular disease (e.g., recent myocardial infarction, serious arrhythmias, unstable angina) - consider risk vs benefit,May cause hypertension, tachycardia, and vasospasm,Avoid in patients with uncontrolled hyperthyroidism or pheochromocytoma,May exacerbate peptic ulcer disease,Use during pregnancy only if benefit outweighs risk; nicotine can cause fetal harm,Do not use in patients with known hypersensitivity to nicotine or components of the formulation
Nicotine replacement therapy should be used with caution in patients with cardiovascular disease, including arrhythmias and angina.,May cause adverse effects in patients with uncontrolled hypertension or hyperthyroidism.,Use caution in patients with peptic ulcer disease or severe renal impairment.,Concomitant smoking while using Nicorette increases risk of nicotine toxicity.
Non-smokers (never smokers or occasional smokers) - risk of addiction,Children under 18 years (unless prescribed),Patients with severe renal impairment (e.g., end-stage renal disease) - risk of accumulation,Pregnancy (unless smoking cessation benefits outweigh risks; alternative therapies preferred),Breastfeeding (avoid use or discontinue nursing due to potential for infant exposure),History of severe cardiovascular disease (e.g., recent MI, life-threatening arrhythmias, unstable angina),Hypersensitivity to nicotine or any component of the product
Hypersensitivity to nicotine or any component of the formulation,Life-threatening arrhythmias (with transdermal patch, but caution with other formulations),Pregnancy (category D; however, benefit may outweigh risk in some cases),Active smoking while using Nicorette (should completely stop smoking before starting)
Avoid acidic beverages (e.g., coffee, juice, soda) immediately before or while using nicotine gum or lozenge, as they can reduce buccal absorption. Food does not affect nicotine patch absorption. Alcohol does not interact directly but may impair judgment regarding smoking cessation.
No specific food interactions; avoid acidic beverages (e.g., coffee, soda, juice) for 15 minutes before and during use of gum or lozenge (not applicable to patch).
Nicotine is teratogenic. First trimester: Increased risk of spontaneous abortion, preterm birth, and low birth weight. Second/third trimester: Impaired fetal lung development, placental insufficiency, and neurobehavioral deficits. No trimester is safe.
Nicotine is a known teratogen. First trimester: Increased risk of spontaneous abortion and congenital anomalies, particularly cardiovascular and musculoskeletal defects. Second and third trimesters: Associated with fetal growth restriction, preterm birth, and stillbirth. Nicotine causes placental vasoconstriction, reducing uteroplacental perfusion.
Nicotine is excreted into breast milk with M/P ratio approximately 2.9. Infant exposure correlates with maternal smoking. Adverse effects include colic, vomiting, diarrhea, and reduced milk production. Breastfeeding is discouraged in women using nicotine replacement therapy.
Nicotine is excreted into breast milk; the M/P ratio is approximately 2.9. Infant exposure can cause adverse effects such as irritability, feeding difficulties, and apnea. Breastfeeding is generally not recommended during nicotine replacement therapy; if used, the lowest effective dose should be chosen and timing adjusted to minimize infant exposure (e.g., feed just before using the product).
Nicotine clearance increases by 60% during pregnancy, reducing plasma concentrations. Dosing may need upward adjustment by 2-4 mg per hour for transdermal patches, or increased gum/lozenge usage frequency. Individualize based on withdrawal symptoms and urine cotinine.
Pregnancy reduces nicotine metabolism due to decreased hepatic clearance, potentially leading to higher systemic exposure. Starting doses should be at the lower end of the recommended range, with titration based on withdrawal symptoms and adverse effects. Avoid higher doses due to risk of fetal toxicity. Use intermittent dosing (e.g., gum, lozenge) rather than transdermal patches to minimize continuous fetal exposure.
Nicotine replacement therapy (NRT) should be used with caution in patients with recent myocardial infarction, serious arrhythmias, or severe angina. Smoking while using NRT can cause nicotine toxicity. The transdermal patch may cause skin irritation; rotate application sites. For rapid symptom relief, gum or lozenge is preferred over patch. Monitor for signs of nicotine overdose: headache, dizziness, nausea, abdominal pain.
Nicotine replacement therapy (NRT) patch; avoid concomitant smoking due to risk of nicotine toxicity; apply to dry, clean, hairless skin; rotate sites to reduce irritation; may be used in pregnancy if benefit outweighs risk; caution in cardiovascular disease; taper dose gradually to prevent withdrawal.
Do not smoke or use any other tobacco products while using nicotine replacement therapy.,If using the patch, apply to a clean, dry, hairless area on the upper body or arm; rotate sites daily.,Chew gum slowly and park between cheek and gum when peppery taste appears; discard after 30 minutes.,For lozenges, allow to dissolve slowly; do not bite or swallow whole.,Seek medical help if you experience symptoms of overdose: severe headache, dizziness, blurred vision, confusion, weakness, vomiting, cold sweat, or difficulty breathing.
Do not smoke or use other nicotine products while using the patch.,Apply patch to clean, dry, hairless skin once daily at same time.,Remove patch after 24 hours and apply new patch to different site.,If you have vivid dreams or sleep disturbance, remove patch at bedtime.,Do not cut or alter the patch; if it falls off, replace with a new one.,Wash hands after application; avoid eye contact with adhesive.,May cause skin redness or itching; contact doctor if severe.,Keep out of reach of children and pets; used patches contain residual nicotine.,Set a quit date and do not use patch before that date if still smoking.
"Dexmedetomidine, a selective alpha-2 adrenergic agonist, may inhibit the metabolism of nicotine through competitive or noncompetitive inhibition of cytochrome P450 enzymes, particularly CYP2A6, leading to increased systemic nicotine exposure. Elevated nicotine levels can potentiate cholinergic adverse effects, including nausea, dizziness, tachycardia, or hypertension, and may increase the risk of nicotine toxicity. Clinical outcomes may include exaggerated cardiovascular responses or diminished tolerance to nicotine replacement therapies or smoking."
"Nicotine, a potent cytochrome P450 (CYP) 3A4 inducer, accelerates the hepatic metabolism of felodipine, a calcium channel blocker primarily metabolized by CYP3A4. This interaction reduces the systemic exposure and peak plasma concentrations of felodipine, potentially diminishing its antihypertensive efficacy. Clinically, patients may experience elevated blood pressure or inadequate angina control, requiring dose adjustment or alternative therapy."
"Nebivolol, a beta-1 selective adrenergic antagonist, can have its antihypertensive and heart rate-lowering effects reduced by the concurrent use of nicotine, primarily due to nicotine's sympathomimetic actions. Nicotine stimulates the release of catecholamines, leading to increased heart rate, blood pressure, and myocardial contractility, which can antagonize the therapeutic effects of nebivolol. This interaction may result in diminished control of hypertension and tachycardia, potentially increasing cardiovascular risk in patients who smoke or use nicotine replacement therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NICOTINE vs NICORETTE, answered by our medical review team.
NICOTINE is a Smoking cessation aid that works by Nicotine is a nicotinic acetylcholine receptor (n ACh R) agonist; binds to α4β2 and α7 subtypes in the central nervous system, causing release of dopamine and other neurotransmitters, leading to stimulation and reward effects. Also acts on peripheral nicotinic receptors affecting autonomic ganglia, neuromuscular junction, and adrenal medulla.. NICORETTE is a Smoking cessation aid that works by Nicotine acts as an agonist at nicotinic acetylcholine receptors, stimulating the release of neurotransmitters such as dopamine and norepinephrine, which reduces withdrawal symptoms and cravings associated with smoking cessation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NICOTINE and NICORETTE depend on the specific clinical indication. These are both Smoking cessation aid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NICOTINE is: Transdermal patch: 21 mg/24 hours applied to dry, non-hairy skin once daily; gum: 2-4 mg chewed as needed (max 24 pieces/day); lozenge: 2-4 mg dissolved as needed (max 20 lozenges/day); inhaler: 6-16 cartridges/day (each 4 mg delivered); nasal spray: 1-2 doses/hour (1 dose = 0.5 mg, 32 mg/day max).. The standard adult dose of NICORETTE is: Nicotine replacement therapy. For smoking cessation, chewing gum: 2 mg or 4 mg piece chewed slowly for 30 minutes every 1-2 hours as needed, maximum 24 pieces/day. Transdermal patch: Apply one 7 mg, 14 mg, or 21 mg/24 hour patch daily. Lozenge: 2 mg or 4 mg lozenge dissolved in mouth every 1-2 hours, maximum 20 lozenges/day. Inhaler: 6-16 cartridges/day. Nasal spray: 1-2 doses/hour, maximum 40 doses/day. All routes: typical duration 8-12 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NICOTINE and NICORETTE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NICOTINE is classified as Category C. Nicotine is teratogenic. First trimester: Increased risk of spontaneous abortion, preterm birth, and low birth weight. Second/third trimester: Impaired fetal lung development, plac. NICORETTE is classified as Category C. Nicotine is a known teratogen. First trimester: Increased risk of spontaneous abortion and congenital anomalies, particularly cardiovascular and musculoskeletal defects. Second and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.